Press Release

View printer-friendly version
<< Back
Aeglea BioTherapeutics Announces FDA Acceptance of Investigational New Drug Application for AEB1102

Austin, Texas (September 14, 2015) – Aeglea BioTherapeutics, Inc., a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s investigational new drug (IND) application for AEB1102 for the treatment of solid tumors. Aeglea intends to initiate a Phase 1 dose escalation study designed to assess the safety, tolerability, and pharmacokinetics of AEB1102 in patients with advanced solid tumors in the fourth quarter of 2015.

“The FDA’s acceptance of our IND is an important organizational milestone for Aeglea as we transition into a clinical-stage company,” said David G. Lowe, Ph.D., co-founder, president and chief executive officer of Aeglea. “We are excited to see our lead product candidate advance into the clinic and move one step closer to bringing this novel therapy to patients in need of new treatment options.”

AEB1102 is an engineered human enzyme designed to degrade the amino acid arginine and in nonclinical studies has demonstrated the ability to reduce blood arginine levels. AEB1102 is being developed to treat cancers that have been shown to have a metabolic dependency on arginine, as well as the rare disease arginase I deficiency, which is caused by an inborn error of metabolism leading to toxic levels of arginine in blood.

About Aeglea BioTherapeutics 

Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in oncology with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine. 

For more information, visit http://aegleabio.com

# # #

Media Contact: 
Kelly France, Ph.D. 
BrewLife 
415.946.1076 
kfrance@brewlife.com